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Macrolide-Resistant Mycoplasma genitalium in Southeastern Region of the Netherlands, 2014-2017
Marta Adelantado, Ana Navascués, Xabier Beristain, Alberto Gil-Setas, Maria E. Portillo, Aitziber Aguinaga, Carmen Ezpeleta Increasing rates of macrolide resistance in M. genitalium are a problem not only in the Netherlands but also worldwide: 77.4% in New Zealand (2) and 41% in the United Kingdom (3) . Macrolide resistance in M. genitalium as a consequence of single-dose azithromycin treatment has been previously reported (4) . European Academy of Dermatology and Venereology guidelines recommend azithromycin in an extended regimen (500 mg day 1,250 mg days 2-5, orally) as a first-line treatment, followed by a test of cure 4-6 weeks after treatment (5) .
In northern Spain, local protocols for the treatment of M. genitalium infections are based on the European guideline. We performed a prospective/retrospective study during August 2015-October 2018. We confirmed 173 cases of M. genitalium infection; mean patient age was 29.4 years, and 57.2% (99/173) were male. We found macrolide-resistant M. genitalium strains in 21.8% (27/124) patients, which is a lower rate than was found in the Netherlands. Most of the patients attending posttreatment follow-up showed wild-type M. genitalium, and only 10.9% (5/46) became resistant to azithromycin treatment, in contrast with 89.6% (60/67) reported by Martens et al. We suggest that the decrease in macrolide resistance resulted from the increased number of posttreatment follow-ups. Our data confirm this. We believe that giving local advice on the basis of extended azithromycin treatment and posttreatment follow-up can limit the spread of macrolide resistance. 
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